BRCA1 and breast cancer: The compound was also in synthetic lethality with loss of BRCA1 as demonstrated by its extreme activity in BRCA1‒/‒ syngeneic cells compared to WT cells and in cells with BRCA1 pathogenic mutations (MDA‐MB‐436 breast cancer and COV362 ovarian cells).117